Drugs / 3VM1001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03421613 | Mar 2017 → Mar 2018 | postherpetic neuralgia | CDA Research Group, Inc. | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT02332148 | Feb → Oct 2015 | osteoarthritis, knee | CDA Research Group, Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3VM1001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03421613 ↗ |
| Route | Topical | “3VM1001 topical cream for treatment of osteoarthritis of the knee” NCT02332148 ↗ |